Nuclisome: a novel concept for radionuclide therapy using targeting liposomes

Fondell, Amelie; Edwards, Katarina; Ickenstein, Ludger M.; Sjöberg, Stefan; Carlsson, Jörgen; Gedda, Lars

doi:10.1007/s00259-009-1225-7

Cited by 36 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By use of cellular assays that permitted quantification of the receptor-mediated uptake of the particles, we could confirm that the Nuclisome-particles are indeed taken up by the cultured cells through interaction with EGFR and HER2, respectively [32,33]. Importantly, the above studies showed that when receptors were blocked with an excess amount of free ligand, or liposomes were administered without targeting agent, the tumor-cell uptake was clearly suppressed.…”

Section: Target Specificitymentioning

confidence: 74%

“…The EGF-PEG-lipid and F5-PEG-lipid conjugates have subsequently been incorporated into liposomes composed of DSPC, cholesterol, and DSPE-PEG2000 (see e.g. [32,33]). Finally, the liposomes have been loaded with iodinated Comp1 using the pH-gradient-driven loading protocol which was first suggested by Mayer et al [34].…”

Section: Target Specificitymentioning

confidence: 99%

“…Receptor specificity was further manifested in an ex vivo human vasculature system (Chandler loop) [32]. In the set up, fresh human blood from healthy donor was mixed with cultured human tumor cells, mimicking circulating tumor cells.…”

Section: Target Specificitymentioning

confidence: 99%

“…The in-vitro evaluation of the Nuclisome-particles has included confocal microscopy and autoradiography studies to verify that the radiolabeled drug, after cellular uptake of the particles, is set free in the cytoplasm and able to translocate to the cell nucleus [32,33]. showed that radioactive decays were co-localized with the nuclei of tumor cells [32], it appears plausible that 125 I causes an Auger effect on tumor-cell DNA.…”

Section: Therapeutic Effect In Vitromentioning

confidence: 99%

“…showed that radioactive decays were co-localized with the nuclei of tumor cells [32], it appears plausible that 125 I causes an Auger effect on tumor-cell DNA.…”

Section: Therapeutic Effect In Vitromentioning

confidence: 99%

See 4 more Smart Citations

Nuclisome—targeting the tumor cell nucleus

Gedda

Edwards

2012

Tumor Biol.

Self Cite

View full text Add to dashboard Cite

The Nuclisome concept builds on a novel two-step targeting strategy with the aim to deliver short-range Auger-electron emitting radionuclides to nuclear DNA of tumor cells.The concept is based on the use of Nuclisome-particles, i.e., tumor-targeted PEGstabilized liposomes loaded with a unique DNA-intercalating compound that enables specific and effective delivery of radionuclides to DNA. The specific and potent two-step targeting leads to eradication of tumor cells while toxicity to normal organs is reduced to a minimum. Results of in vitro and in vivo studies point towards the Nuclisome concept as a promising strategy for treatment of small tumor masses and, in particular, elimination of spread single cells and micrometastases.3

show abstract

Section: Target Specificitymentioning

confidence: 74%

Section: Target Specificitymentioning

confidence: 99%

Section: Target Specificitymentioning

confidence: 99%

Section: Therapeutic Effect In Vitromentioning

confidence: 99%

“…showed that radioactive decays were co-localized with the nuclei of tumor cells [32], it appears plausible that 125 I causes an Auger effect on tumor-cell DNA.…”

Section: Therapeutic Effect In Vitromentioning

confidence: 99%

See 3 more Smart Citations

Nuclisome—targeting the tumor cell nucleus

Gedda

Edwards

2012

Tumor Biol.

Self Cite

View full text Add to dashboard Cite

show abstract

Immunonanoparticles for Nuclear Imaging and Radiotherapy

Giladi

Benita

2012

Antibody‐Mediated Drug Delivery Systems

View full text Add to dashboard Cite

Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis?

Pant

Sedláček

Nadar

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

Owing to their tunable blood circulation time and suitable plasma stability, polymer-based nanomaterials hold a great potential for designing and utilising multifunctional nanocarriers for efficient imaging and effective treatment of cancer. When tagged with appropriate radionuclides, they may allow for specific detection (diagnosis) as well as the destruction of tumours (therapy) or even customization of materials, aiming to both diagnosis and therapy (theranostic approach). This review provides an overview of recent developments of radiolabelled polymeric nanomaterials (natural and synthetic polymers) for molecular imaging of cancer, specifically, applying nuclear techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Different approaches to radiolabel polymers are evaluated from the methodical radiochemical point of view. This includes new bifunctional chelating agents (BFCAs) for radiometals as well as novel labelling methods. Special emphasis is given to eligible strategies employed to evade the mononuclear phagocytic system (MPS) in view of efficient targeting. The discussion encompasses promising strategies currently employed as well as emerging possibilities in radionuclide-based cancer therapy. Key issues involved in the clinical translation of radiolabelled polymers and future scopes of this intriguing research field are also discussed.

show abstract

Nuclisome: a novel concept for radionuclide therapy using targeting liposomes

Abstract: The results thus provide encouraging evidence that our two-step targeting strategy for tumour cell DNA has the potential to become an effective therapy against metastasizing cancer cells in the bloodstream.

Cited by 36 publications

References 21 publications

Nuclisome—targeting the tumor cell nucleus

Nuclisome—targeting the tumor cell nucleus

Immunonanoparticles for Nuclear Imaging and Radiotherapy

Radiolabelled Polymeric Materials for Imaging and Treatment of Cancer: Quo Vadis?

Contact Info

Product

Resources

About